Floatz logo

pds0101

HIV Infectious Disease

Weill Medical College of Cornell UniversityUNKNOWNPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

58 Active assets in the HIV Infectious Disease cohort.

Asset / SponsorPhaseRating
Raltegravir
Helsinki University Central Hospital
Phase 4A
Efavirenz
The Cleveland Clinic
Phase 4BBB
Retrovir
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BBB
Nevirapine Anhydrous
Germans Trias i Pujol Hospital
Phase 4BBB
NORVIR
Giovanni Di Perri
Phase 4BBB

View all 46 →

Same molecule, other indications

pds0101 is also rated in:

anal carcinomaActive
B
Indicative · Phase 2
58 / 100
View asset →
cervical cancerActive
CCC
Indicative · Phase 2
55 / 100
View asset →
oropharyngeal carcinomaDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →